Price movement over the last 24 hours
Alcon AG vs Bath & Body Works Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Bath & Body Works Inc trades at $19.4 (market cap $4.16B). The key difference: Alcon AG is far larger — about 7.9× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (3.88%). Which is the better fit depends on your goals.
| ALC | BBWI | |
|---|---|---|
Market Cap | $32.69B | $4.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $33.65 |
52-Week Low | $62.02 | $14.85 |
Enterprise Value | $36.28B | $8.05B |
Dividend Yield | 0.54% | 3.88% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BBWI trades at $20.62, down 6.1% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock is valued attractively with a P/E of 6.23 and P/S of 0.62, while recent earnings beat expectations in Q1 2026. Revenue has declined over five years, but the company maintains strong cash flow and a new partnership with Ulta Beauty aims to expand reach.
The outlook is mixed: deep valuation discounts and strategic initiatives like the Ulta partnership offer upside, but persistent revenue declines and high debt pose risks. Analyst consensus is a $22.50 price target with no sell ratings, indicating cautious optimism for a turnaround if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →